Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD

Neuroscience Letters

Volumn 481, Issue 2, 2010, Pages 88-91

  Kawajiri, Sumihiro ^a   Machida, Yutaka ^b   Saiki, Shinji ^a   Sato, Shigeto ^a   Hattori, Nobutaka ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

Author keywords

Apoptosis; Manganese superoxide dismutase; Parkinson's disease; Zonisamide

Indexed keywords

LEVODOPA; MANGANESE SUPEROXIDE DISMUTASE; ZONISAMIDE;

APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG MECHANISM; HUMAN; HUMAN CELL; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 77955272981     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.06.058     Document Type: Article

References (31)

1. Asanuma M., Miyazaki I., Diaz-Corrales F.J., Kimoto N., Kikkawa Y., Takeshima M., Miyoshi K., Murata M. Neuroprotective effects of zonisamide target astrocyte. Ann. Neurol. 2010, 67:239-249.
2. Asanuma M., Miyazaki I., Diaz-Corrales F.J., Miyoshi K., Ogawa N., Murata M. Preventing effects of a novel anti-Parkinsonian agent zonisamide on dopamine quinone formation. Neurosci. Res. 2008, 60:106-113.
3. Ben-Shachar D., Riederer P., Youdim M.B. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 1991, 57:1609-1614.
4. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A. 1983, 80:4546-4550.
5. Carvey P.M., Punati A., Newman M.B. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant. 2006, 15:239-250.
6. Djavaheri-Mergny M., Javelaud D., Wietzerbin J., Besancon F. NF-kappaB activation prevents apoptotic oxidative stress via an increase of both thioredoxin and MnSOD levels in TNFalpha-treated Ewing sarcoma cells. FEBS Lett. 2004, 578:111-115.
7. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:1956-1961.
8. Klivenyi P., St Clair D., Wermer M., Yen H.C., Oberley T., Yang L., Flint Beal M. Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiol. Dis. 1998, 5:253-258.
9. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
10. Langston J.W., Irwin I., Langston E.B., Forno L.S. Pargyline prevents MPTP-induced Parkinsonism in primates. Science 1984, 225:1480-1482.
11. Machida Y., Chiba T., Takayanagi A., Tanaka Y., Asanuma M., Ogawa N., Koyama A., Iwatsubo T., Ito S., Jansen P.H., Shimizu N., Tanaka K., Mizuno Y., Hattori N. Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. Biochem. Biophys. Res. Commun. 2005, 332:233-240.
12. Manna S.K., Zhang H.J., Yan T., Oberley L.W., Aggarwal B.B. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J. Biol. Chem. 1998, 273:13245-13254.
13. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 1989, 163:1450-1455.
14. Mori A., Noda Y., Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res. 1998, 30:153-158.
15. Murata M., Hasegawa K., Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007, 68:45-50.
16. Murata M, Horiuchi E., Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci. Res. 2001, 41:397-399.
17. Noda K., Kitami T., Gai W.P., Chegini F., Jensen P.H., Fujimura T., Murayama K., Tanaka K., Mizuno Y., Hattori N. Phosphorylated IkappaBalpha is a component of Lewy body of Parkinson's disease. Biochem. Biophys. Res. Commun. 2005, 331:309-317.
18. Okada M., Kaneko S., Hirano T., Mizuno K., Kondo T., Otani K., Fukushima Y. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995, 22:193-205.
19. Okouchi M., Ekshyyan O., Maracine M., Aw T.Y. Neuronal apoptosis in neurodegeneration. Antioxid. Redox Signal. 2007, 9:1059-1096.
20. Perier C., Tieu K., Guegan C., Caspersen C., Jackson-Lewis V., Carelli V., Martinuzzi A., Hirano M., Przedborski S., Vila M. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:19126-19131.
21. Pham C.G., Papa S., Bubici C., Zazzeroni F., Franzoso G. Oxygen JNKies: phosphatases overdose on ROS. Dev. Cell 2005, 8:452-454.
22. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
23. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 2004, 318:215-224.
24. Sharma M., Sharma P., Pant H.C. CDK-5-mediated neurofilament phosphorylation in SHSY5Y human neuroblastoma cells. J. Neurochem. 1999, 73:79-86.
25. Shimazawa M., Nakajima Y., Mashima Y., Hara H. Docosahexaenoic acid (DHA) has neuroprotective effects against oxidative stress in retinal ganglion cells. Brain Res. 2009, 1251:269-275.
26. Stefanis L., Larsen K.E., Rideout H.J., Sulzer D., Greene L.A. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 2001, 21:9549-9560.
27. Xia Z, Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331.
28. Yabe H., Choudhury M.E., Kubo M., Nishikawa N., Nagai M., Nomoto M. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J. Pharmacol. Sci. 2009, 110:64-68.
29. Yano R., Yokoyama H., Kuroiwa H., Kato H., Araki T. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice. J. Mol. Neurosci. 2009, 39:211-219.
30. Yokoyama H, Yano R., Kuroiwa H., Tsukada T., Uchida H., Kato H., Kasahara J., Araki T. Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)neurotoxicity in mice. Metab. Brain Dis. 2010, 25:135-143.
31. Zhao Y., Kiningham K.K., Lin S.M., St Clair D.K. Overexpression of MnSOD protects murine fibrosarcoma cells (FSa-II) from apoptosis and promotes a differentiation program upon treatment with 5-azacytidine: involvement of MAPK and NFkappaB pathways. Antioxid. Redox Signal. 2001, 3:375-386.